ARGX vs RPRX
argenx SE vs Royalty Pharma plc — AI-powered side-by-side comparison
VS
RPRX
Royalty Pharma plc
56
Watch
| Metric | ARGX | RPRX |
|---|
| AI Score |
69
|
56
|
| Price |
$864.40
|
$57.79
|
| P/E Ratio |
31.34×
|
23.98×
|
| ROE |
17.6%
|
11.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
89.4%
|
| Debt / Equity |
0.01×
|
1.31×
|
| Dividend Yield |
0.0%
|
1.6%
|
| RSI (14) |
47.9
|
49.6
|
| Beta |
-0.022
|
0.425
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ARGX versus RPRX.
ARGX leads by 13 points.
ARGX scores 69/100 (Buy) versus RPRX at 56/100 (Watch).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
RPRX Committee View
60% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 40.9 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 40.9 is expensive by classic value standards — Value
- EPS declining -15.9% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical